ClinicalTrials.gg
RecruitingNCT05539677REGATAUpdated May 6, 2024

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

An observational study in Malignant Solid Tumors, Primary Brain Tumor and Melanoma, sponsored by N.N. Petrov National Medical Research Center of Oncology. Recruiting at 1 site in Russian Federation. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2024-05-06.

Sponsored by N.N. Petrov National Medical Research Center of Oncology · Observational

How we know

From the registry’s dates

  • Started Sep 1998; still recruiting 28 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Brain Neoplasms with a site in Russian Federation — 1 open to participants now, 1 under way, none of them phase 3. Brain Neoplasms · Russian Federation.

Started
1998
the only one that year
Observational
Only one
of the 13
Registered
13th of 13
by date
Lead sponsor
1 of 13
N.N. Petrov National Medical Research Center of Oncology

Among the 13 studies in Brain Neoplasms with a site in Russian Federation, this one is the only one that started in 1998, is the only observational one, and was the 13th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

1 of the 13 studies in Brain Neoplasms with a site in Russian Federation is open now.

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Brain Neoplasms with a site in Russian Federation, or all of them as a file.
02

Study summary

The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies

03

Conditions studied

  • Malignant Solid Tumors
  • Primary Brain Tumor
  • Melanoma
  • Soft Tissue Sarcoma
  • Colorectal Cancer
  • Kidney Cancer
  • Prostate Cancer
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study will include patients with solid tumours receiving systemic therapy for their disease who do not have other significant factors that affect the immune system

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed inform consent
  • Histolgically verified solid tumour
  • Receiving systemic therapy for neoplasm
  • Has
  • Provide biosamples with living tumour tissue or blood samples for immunologic assessment

Exclusion criteria

Exclusion Criteria:

  • Concurrent Lymphoprolipherative disorder
  • Patients after stem cell or bone marrow thansplantation
  • Incomplete informaton on previous cancer history or medical history
  • Patients with known primary immunodeficiency
  • Patients receiving immunosupressive therapy for concurrent illness
  • Pregnant patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Melanoma
  • Soft tissue sarcoma
  • Kidney cancer
  • Primary brain tumors
  • Malignant neoplasms
  • Prostate cancer
  • Colorectal cancer
06

What researchers measure

Primary outcomes

  1. Progression in 3 mo

    Presence of disease progression within 3 mo from sample aquisition

    Time frame: 3 month

Secondary outcomes

  1. Overall survival (OS)

    Time from sample aquisition to death from any reason

    Time frame: Up to 5 years

  2. Progression free survival

    Time from sample aquisition to progression or death from the disease

    Time frame: Up to 5 years

  3. Response rate

    Response assesmenr with RECIST 1.1 and iRECIST

    Time frame: During the intervention

07

Study locations

1 of 1 sites recruiting
  • N.N. Petrov NMRC of Oncology, Oncoimmunology dep.
    Saint Petersburg, 197758, Russian Federation
    Recruiting
08

References and documents

Publications

  • Shendaleva N, Novik AV, Zozulya A, Nekhaeva TL, Semenova A, Teletaeva GM, et al. Impact of the azoximer bromide concomitant therapy on patient outcomes in patients with melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(15_suppl):e21574-e.
  • Novik AV, Shendaleva N, Zozulya A, Nekhaeva TL, Semenova A, Teletaeva GM, et al. Impact of the azoximer bromide concomitant therapy on outcomes in patients with soft tissue sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(15_suppl):e23534-e.
  • Novik AV, Girdyuk DV, Nekhaeva TL, Emelyanova NV, Semenova A, Teletaeva GM, et al. Progression prediction model for solid tumors with clinical and immunological parameters. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(15_suppl):2539.

Individual participant data

Plan to share: Undecided — Upon completion, the database is planned to be published with depersonalized data for cohorts with meaningful data. Cohorts to be published will be defined upon data check. Partial publications could be applicable.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 1998 (actual). Primary completion is estimated for Dec 2030, 387 months after the start.

Of 182 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's planned 387 months is above that.

Counting every sponsor, half of 200 studies reached it within 82 months; a quarter within 41 and three quarters within 269.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2022
First posted
Sep 14, 2022
StartActual
Sep 1998
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
May 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05539677
Lead sponsor
N.N. Petrov National Medical Research Center of Oncology
Responsible party
Sponsor
First posted
Sep 14, 2022
Start date
Sep 1998
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
May 6, 2024

Study contacts

Aleksei Novik, MD, PhD
Contact
alexey.viktorovich.novik@gmail.com
+78124399505
Tatiana Nekhaeva, MD, PhD
Contact
nehaevat151274@mail.ru
+78124399514
Irina Baldueva, MD, PhD, DSc
study director · N.N. Petrov NMRC of Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion